Items where Author is "Angelis, Aris"

Item Type No Grouping

Funding sources of therapeutic and vaccine clinical trials for COVID-19 vs non-COVID-19 indications, 2020-2021. (2022) Angelis, Aris and Suarez Alonso, Carlos and Kyriopoulos, Ilias and Mossialos, Elias picture_as_pdf

Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. (2018) Angelis, Aris and Lange, Ansgar and Kanavos, Panos

Acquiring pharmaceutical industry assets in the UK: 1 + 1 = 1? Kanavos, Panos and Angelis, Aris

Advancing structured decision-making in drug regulation at the FDA and EMA. Angelis, Aris and Phillips, Lawrence D. picture_as_pdf

Applying multiple criteria decision analysis to comparative benefit-risk assessment: choosing among statins in primary prevention. Tervonen, Tommi and Naci, Huseyin and van Valkenhoef, Gert and Ades, Anthony E. and Angelis, Aris and Hillege, Hans L. and Postmus, Douwe

Comment on: “Does MCDA trump CEA?”. Angelis, Aris and Kanavos, Panos picture_as_pdf

Critique of the American Society of Clinical Oncology value assessment framework for cancer treatments: putting methodologic robustness first. Angelis, Aris and Kanavos, Panos

Direct cost of pars plana vitrectomy for the treatment of macular hole, epiretinal membrane and vitreomacular traction: a bottom-up approach. Nicod, Elena and Jackson, Timothy L. and Grimaccia, Federico and Angelis, Aris and Costen, Marc and Haynes, Richard and Hughes, Edward and Pringle, Edward and Zambarakji, Hadi and Kanavos, Panos

An EU-wide approach to HTA:an irrelevant development or an opportunity not to be missed? Kanavos, Panos and Angelis, Aris and Drummond, Michael

Early health technology assessment during nonalcoholic steatohepatitis drug development:a two-round, cross-country, multicriteria decision analysis. Angelis, Aris and Thursz, Mark and Ratziu, Vlad and O'Brien, Alistair and Serfaty, Lawrence and Canbay, Ali and Schiefke, Ingolf and Bana e Costa, João C. and Lecomte, Pascal and Kanavos, Panos picture_as_pdf

Evaluating the benefits of new drugs in health technology assessment using multiple criteria decision analysis: a case study on metastatic prostate cancer with the dental and pharmaceuticals benefits agency (TLV) in Sweden. Angelis, Aris

High drug prices are not justified by industry’s spending on research and development. Angelis, Aris and Polyakov, Roman and Wouters, Olivier J. and Torreele, Els and McKee, Martin picture_as_pdf

ICER value framework 2020 update:recommendations on the aggregation of benefits and contextual considerations. Angelis, Aris and Kanavos, Panos and Phillips, Lawrence D. picture_as_pdf

The Innovative Medicines Fund:a universal model for faster and fairer access to new promising medicines or a Trojan horse for low-value creep? Angelis, Aris and Aggarwal, Ajay and Miners, Alec and Cairns, John and Briggs, Andrew picture_as_pdf

Is the funding of public national health systems sustainable over the long term? Evidence from eight OECD countries. Angelis, Aris and Tordrup, David and Kanavos, Panos

Large scale mergers and acquisitions in the pharmaceutical industry: 1 + 1 = 1? Angelis, Aris and Kanavos, Panos

Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: the Advance Value Framework. Angelis, Aris and Kanavos, Panos

Multiple criteria decision analysis for HTA across four EU member states:piloting the Advance Value Framework. Angelis, Aris and Linch, Mark and Montibeller, Gilberto and Molina Lopez, Maria Teresa and Zawada, Anna and Orzel, Kinga and Arickx, Francis and Espin, Jaime and Kanavos, Panos picture_as_pdf

Multiple criteria decision analysis for valuebased assessment of new medical technologies:a conceptual framework. Kanavos, Panos and Angelis, Aris

Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. Angelis, Aris and Montibeller, Gilberto and Hochhauser, Daniel and Kanavos, Panos

Pars plana vitrectomy for diabetic macular edema: a systematic review, meta-analysis, and synthesis of safety literature. Jackson, Timothy L. and Nicod, Elena and Angelis, Aris and Grimaccia, Federico and Pringle, Edward and Kanavos, Panos

Pars plana vitrectomy for vitreomacular traction syndrome: a systematic review and metaanalysis of safety and efficacy. Jackson, Timothy L. and Nicod, Elena and Angelis, Aris and Grimaccia, Federico and Prevost, Andrew T. and Simpson, Andrew R.H. and Kanavos, Panos

Preferences on policy options for ensuring the financial sustainability of health care services in the future: results of a stakeholder survey. Tordrup, David and Angelis, Aris and Kanavos, Panos

Quantifying preference in drug benefit-risk decisions. Tervonen, Tommi and Angelis, Aris and Hockley, Kimberley and Pignatti, Francesco and Phillips, Lawrence D. picture_as_pdf

Recalibrating health technology assessment methods for cell and gene therapies. Angelis, Aris and Naci, Huseyin and Hackshaw, Allan picture_as_pdf

Resource allocation and priority setting in health care: a multi-criteria decision analysis problem of value? Angelis, Aris and Kanavos, Panos and Montibeller, Gilberto

Socio-economic burden of rare diseases: a systematic review of cost of illness evidence. Angelis, Aris and Tordrup, David and Kanavos, Panos

Symptomatic vitreomacular adhesion. Jackson, Timothy and Nicod, Elena and Simpson, Andrew and Angelis, Aris and Grimaccia, Federico and Kanavos, Panos

Use of the ESMO-magnitude of clinical benefit scale to guide HTA recommendations on coverage and reimbursement for cancer medicines:a retrospective analysis. Kanavos, Panos and Visintin, Erica and Angelis, Aris picture_as_pdf

Value-based assessment of new medical technologies: towards a robust methodological framework for the application of multiple criteria decision analysis in the context of health technology assessment. Angelis, Aris and Kanavos, Panos

Vitreous attachment in age-related macular degeneration, diabetic macular edema, and retinal vein occlusion. Jackson, Timothy L. and Nicod, Elena and Angelis, Aris and Grimaccia, Federico and Prevost, Toby and Simpson, Andrew and Kanavos, Panos

Why are the prices of new medicines so high and what can we do about it? (F8). Angelis, Aris

The evolving nature of Health Technology Assessment:a critical appraisal of NICE’s new methods manual. Angelis, Aris and Harker, Martin and Cairns, John and Seo, Mikyung Kelly and Legood, Rosa and Miners, Alec and Wiseman, Virginia and Chalkidou, Kalipso and Grieve, Richard and Briggs, Andrew picture_as_pdf

The need for novel approaches in assessing the value of COVID-19 vaccines. Angelis, Aris and Baltussen, Rob and Tervonen, Tommi

A structured methodology for essential medicines lists and health emergency stockpiles:experience with the Emergency Medicines Buffer Stock in the United Kingdom. Angelis, Aris and Montibeller, Gilberto Neto and Kanavos, Panos picture_as_pdf